Endologix Announces Collaboration Agreements with Japan Lifeline for the Development and Commercialization of Thoracic Endovascular Systems in Japan
Under the terms of these agreements, the two companies will jointly
invest in the development, clinical research, and commercialization of
the Systems. JLL has exclusive distribution rights to the Systems in
"JLL is our exclusive distributor in
About Japan Lifeline Co., Ltd.
Japan Lifeline (JLL) has a 36-year history as a manufacturer, importer and distributor of quality medical products. JLL has a strong track record of success in building and expanding markets with unique products from some of the world's leading medical technology companies. Japan Lifeline is a publicly traded company, ticker symbol 7575 (TSE 1st Section). For more information, visit www.japanlifeline.com.
Cautions Regarding Forward-Looking Statements
Except for historical information contained herein, this press
release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements generally can be identified by the use of words such as
"anticipate," "expect," ‘plan,' "could," "may,""will," "believe,"
"estimate," "forecast," "goal," "project," "continue," "outlook,"
"guidance," "future," other words of similar meaning and the use of
future dates. Forward-looking statements used in this press release
include, but are not limited to, statements regarding product research,
development and commercialization, anticipated product markets, timing
of anticipated product launches, and anticipated benefits and effects of
our agreements with JLL, accuracy of which are necessarily subject to
risks and uncertainties that may cause future events to differ
materially and adversely from the statements contained herein. Some of
the potential risks and uncertainties that could cause actual results to
differ materially and adversely include Endologix's ability to realize
the expected benefits of the transactions with JLL, competition from
other products, changes to applicable laws and regulations, product
development risks, clinical trial risks (including clinical trial
results), decisions and the timing of decisions of regulatory
authorities regarding our current and future products, financial
constraints, risks relating to foreign currency fluctuations, and a
variety of other risks. Undue reliance should not be placed upon the
forward-looking statements contained in this press release, which speak
only as of the date of this press release.
News Provided by Acquire Media